Evidence map›Paper›PMID 38868945›Full record

ArticleJournal of extracellular vesicles2024

Inter-laboratory multiplex bead-based surface protein profiling of MSC-derived EV preparations identifies MSC-EV surface marker signatures.

Vivian V T Nguyen, Joshua A Welsh, Tobias Tertel, Andre Choo, Simonides I van de Wakker, Kyra A Y Defourny, Bernd Giebel, Pieter Vader, Jayanthi Padmanabhan, Sai Kiang Lim and 9 more

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in Journal of extracellular vesicles, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Vivian V T NguyenDepartment of Nephrology and Hypertension, UMC Utrecht, Utrecht, The Netherlands.
Joshua A WelshTranslational Nanobiology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-1097-9756
Tobias TertelInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0001-8659-8610
Andre ChooBioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Simonides I van de WakkerDepartment of Cardiology, Experimental Cardiology Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Kyra A Y DefournyDivision of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Bernd GiebelInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Pieter VaderDepartment of Cardiology, Experimental Cardiology Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-7059-8920
Jayanthi PadmanabhanBioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Sai Kiang LimBioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID https://orcid.org/0000-0002-5752-3297
Esther N M Nolte-'t HoenDivision of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Marianne C VerhaarDepartment of Nephrology and Hypertension, UMC Utrecht, Utrecht, The Netherlands.
R Beklem BostanciogluDivision of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Antje M ZicklerDivision of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Jia Mei HongBioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Jennifer C JonesTranslational Nanobiology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Samir El AndaloussiDivision of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Bas W M van BalkomDepartment of Nephrology and Hypertension, UMC Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-3204-2059
André GörgensInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0001-9198-0857

Funding

Development and use of nanoFACS for analysis and sorting of nanoparticlesZIABC011502 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JONES, JENNIFER · 2013 to 2025
$8.6M
Novel Combinations of Radiation and ImmunotherapyZIABC011503 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JONES, JENNIFER · 2013 to 2025
$5.3M
Identification of Specific Macromolecular Complexes in Liquid BiopsiesZIABC012107 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JONES, JENNIFER · 2022 to 2025
$339k
Dutch Heart Foundation CVON2014-11 'RECONNECT'Dutch Heart Foundation 'RECONNEXT'Dutch Society for the Replacement of Animal TestingFourth Framework Programme H2020 research and innovation programme under MariHealth∼Holland TKI-LSH LSHM18045IAF-PP HHP domain H19H6a0026International Society for Advancement of CytometryKarolinska Institutet Network Medicine Global Alliance grantNetherlands Organization for Scientific Research 024.003.013RECONNECT YTP 'CHIPS' grantUniversiteit Utrecht 3Rs stimulus fund project "MOOI!"Van Herk Foundation
6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are promising regenerative therapeutics that primarily exert their effects through secreted extracellular vesicles (EVs). These EVs - being small and non-living - are easier to handle and possess advantages over cellular products. Consequently, the therapeutic potential of MSC-EVs is increasingly investigated. However, due to variations in MSC-EV manufacturing strategies, MSC-EV products should be considered as highly diverse. Moreover, the diverse array of EV characterisation technologies used for MSC-EV characterisation further complicates reliable interlaboratory comparisons of published data. Consequently, this study aimed to establish a common method that can easily be used by various MSC-EV researchers to characterise MSC-EV preparations to facilitate interlaboratory comparisons. To this end, we conducted a comprehensive inter-laboratory assessment using a novel multiplex bead-based EV flow cytometry assay panel. This assessment involved 11 different MSC-EV products from five laboratories with varying MSC sources, culture conditions, and EV preparation methods. Through this assay panel covering a range of mostly MSC-related markers, we identified a set of cell surface markers consistently positive (CD44, CD73 and CD105) or negative (CD11b, CD45 and CD197) on EVs of all explored MSC-EV preparations. Hierarchical clustering analysis revealed distinct surface marker profiles associated with specific preparation processes and laboratory conditions. We propose CD73, CD105 and CD44 as robust positive markers for minimally identifying MSC-derived EVs and CD11b, CD14, CD19, CD45 and CD79 as reliable negative markers. Additionally, we highlight the influence of culture medium components, particularly human platelet lysate, on EV surface marker profiles, underscoring the influence of culture conditions on resulting EV products. This standardisable approach for MSC-EV surface marker profiling offers a tool for routine characterisation of manufactured EV products in pre-clinical and clinical research, enhances the quality control of MSC-EV preparations, and hopefully paves the way for higher consistency and reproducibility in the emerging therapeutic MSC-EV field.

Indexed as

Extracellular VesiclesFlow CytometryMembrane ProteinsMesenchymal Stem CellsProtein Array AnalysisHEK293 CellsHumansLaboratoriesMicrospheresMembrane Proteinsculture conditionsexosomesextracellular vesiclesinter‐laboratory assessmentmesenchymal stromal cellsMSCMSC‐markerquality controlregenerative medicinestandardisationsurface markers

Identifiers

PMID38868945
PMCPMC11170075

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.